Selling, General, and Administrative Costs: BioCryst Pharmaceuticals, Inc. vs Novavax, Inc.

A Tale of Two Biotechs: BioCryst vs. Novavax

In the ever-evolving landscape of biotechnology, understanding the financial health of companies is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of BioCryst Pharmaceuticals, Inc. and Novavax, Inc. over the past decade. From 2014 to 2023, BioCryst's SG&A costs surged by nearly 2800%, reflecting its aggressive expansion and strategic investments. Meanwhile, Novavax's expenses skyrocketed by over 2300%, peaking in 2022, likely due to its pivotal role in the global vaccine race. By 2023, Novavax's SG&A expenses were more than double those of BioCryst, highlighting its larger operational scale. This financial narrative underscores the dynamic nature of biotech firms as they navigate innovation, competition, and market demands. Dive deeper into these trends to understand the strategic decisions shaping the future of these industry players.